0021-972X/06/$15.00/0
Printed in U.S.A.

The Journal of Clinical Endocrinology & Metabolism 91(7):2562–2568

doi: 10.1210/jc.2005-2799

Metabolic Factors Associated with Benign Prostatic Hyperplasia

J. Kellogg Parsons, H. Ballentine Carter, Alan W. Partin, B. Gwen Windham, E. Jeffrey Metter, Luigi Ferrucci, Patricia Landis, and Elizabeth A. Platz

The James Buchanan Brady Urological Institute (J.K.P., H.B.C., A.W.P., P.L., E.A.P.), The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287; The National Institute of Aging, Clinical Research Branch (B.G.W., E.J.M., L.F.), Harbor Hospital, Baltimore, Maryland 21225; and The Department of Epidemiology (E.A.P.), The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205

Context: Benign prostatic hyperplasia poses a significant public health problem, but its etiology remains unclear. Obesity and associated abnormalities in glucose homeostasis may play a role in benign prostatic hyperplasia development by influencing prostate growth.

Objective: The objective of this study was to determine whether obesity, fasting plasma glucose concentration, and diabetes are associated with radiologically determined prostate enlargement, an objective measure of benign prostatic hyperplasia.

Design: This study was a cross-sectional analysis with robust variance estimates to account for multiple measures over time in the same individuals.

Setting: This prospective cohort study was composed of community volunteers.

Patients: Patients studied were 422 adult men enrolled in The Baltimore Longitudinal Study of Aging.

Main Outcome Measurements: Total prostate volume as determined by pelvic magnetic resonance imaging was measured.

Results: Among 422 participants, 91 (21.6%) had prostate enlargement (defined as total prostate volume $\geq$ 40 cc) at first visit. Compared with men of normal weight [body mass index (BMI) $<$ 25 kg/m^2], the age-adjusted odds ratio (OR) for prostate enlargement for overweight men (BMI, 25–29.9 kg/m^2) was 1.41 (95% CI, 0.84–2.37), for obese men (BMI, 30–34 kg/m^2) was 1.27 (95% CI, 0.68–2.39), and for severely obese men (BMI $\geq$ 35 kg/m^2) was 3.52 (95% CI, 1.45–8.56) ($P = 0.01$). Men with elevated fasting glucose (>110 mg/dl) were more likely to have an enlarged prostate than men with normal fasting glucose ($\leq$110 mg/dl) (OR, 2.98; 95% CI, 1.70–5.23), as were men with a diagnosis of diabetes (OR, 2.25; 95% CI, 1.23–4.11).

Conclusions: Obesity, elevated fasting plasma glucose, and diabetes are risk factors for benign prostatic hyperplasia. **(*J Clin Endocrinol Metab* 91: 2562–2568, 2006)**

BENIGN PROSTATIC HYPERPLASIA is a highly prevalent disease of older men caused by nonmalignant, unregulated growth of the prostate gland. In severe cases, benign prostatic hyperplasia may cause sepsis, irreversible bladder damage, renal failure, or death (1). The prevalence among U.S. men aged 60 yr or older is 40% and among men aged 80 yr or older is 90% (1). Globally, the prevalence among men aged 60 yr or older exceeds 50% (2, 3). In 2000, the most recent year for which comprehensive data are available, benign prostatic hyperplasia generated 1.1 billion dollars in health care expenditures and accounted for over 4.4 million office visits, 117,000 emergency room visits, and 105,000 hospitalizations in the United States (4).

The etiology of benign prostatic hyperplasia is not well understood. Androgens, essential for normal prostate growth and development, play a prominent role (5, 6). However, there is also evidence that metabolic disturbances may promote prostate hyperplasia and benign prostatic hyperplasia pathogenesis. IGFs are potent inducers of prostate growth *in vitro* (7, 8), and higher serum concentrations of insulin and IGF-I are associated with clinical benign prostatic hyperplasia (9, 10).

The metabolic syndrome is a clinical constellation of metabolic abnormalities associated with an increased risk of cardiovascular disease. Two principal components of the metabolic syndrome are obesity and abnormal glucose homeostasis (11). Although some prior observational studies have detected associations of obesity (9, 12, 13) and abnormal glucose homeostasis (9, 14) with benign prostatic hyperplasia, others have not (15–17). All of these prior studies used surgery for prostate enlargement and/or lower urinary tract symptoms as surrogate measures of clinical benign prostatic hyperplasia. The specificity of these surrogates is uncertain, which may in part explain the inconsistency of prior findings.

Prostate volume, in contrast, is an objective, quantitative measure of benign prostatic hyperplasia and a strong predictor of adverse clinical outcomes (18, 19). Some studies have observed positive associations of obesity (20–25) and serum insulin concentration (21, 26) with prostate volume.

Obesity and abnormal glucose homeostasis, like benign prostatic hyperplasia, are highly prevalent among older men (27, 28). Further analysis of obesity, abnormal glucose homeostasis, and prostate volume may yield substantive clues to benign prostatic hyperplasia etiology and suggest novel interventions for prevention and treatment. Therefore, we

First Published Online April 11, 2006

Abbreviations: BLSA, Baltimore Longitudinal Study of Aging; BMI, body mass index; MRI, magnetic resonance imaging; OR, odds ratio; PSA, prostate-specific antigen.

JCEM is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.

examined the associations of obesity, fasting plasma glucose concentration, and diabetes with serial measures of prostate volume in an ongoing prospective of study of aging.

Patients and Methods

Study participants

The Baltimore Longitudinal Study of Aging (BLSA) is an ongoing, open cohort study of the physiology of aging directed by the U.S. National Institute on Aging and approved by the combined Institutional Review Board of the Johns Hopkins Medical Institutions and the Gerontology Research Center of the National Institute on Aging. Participants generally represent higher socioeconomic strata and return at approximately 2-yr intervals for comprehensive physiological, psychological, and biochemical testing (29).

Between January 1, 1993 and July 1, 2002, male participants in the BLSA underwent serial prostate examinations and anthropometric measures. At every visit, each man underwent pelvic magnetic resonance imaging (MRI) analysis of prostate volume. In addition, the following anthropometric and urological evaluations were performed: height, weight, waist circumference, and hip circumference measurement; digital rectal examination by a urologist; serum prostate-specific antigen (PSA) testing; and lower urinary tract symptom assessment with a validated questionnaire. In accordance with established clinical guidelines, men with a serum PSA concentration more than or equal to 4.0 ng/ml and/or an abnormal digital rectal examination underwent prostate biopsy for the detection of prostate cancer.

A total of 540 men had 1100 separate prostate MRI volume measurements during the study period. We excluded those men with a history of prostate cancer before the study or those diagnosed with prostate cancer during the study (n = 42); those with incomplete PSA data because lack of PSA screening potentially may have altered the opportunity for prostate cancer detection in these men (n = 6); those with incomplete anthropometric data (n = 30); those taking finasteride, a medication that decreases prostate volume (n = 20); and those who had undergone surgery for prostate enlargement before the study (n = 20). Men who underwent surgery for prostate enlargement during the study were censored at date of surgery. This left 422 men with 791 serial prostate volume measurements. Of these, 219 (52%) had two or more serial volume measurements (median, two measurements per participant; range, one to five measurements per participant). The mean time interval between repeated measurements was 2.7 yr (median, 2.1 yr; range, 1.7–7.7 yr).

Corresponding anthropometric data and diabetes status were available for all 791 prostate volume measurements. As part of a separate study, fasting plasma glucose levels were measured in BLSA men between January 1993 and June 2002 (30). Because obese and diabetic men are known to have lower serum testosterone concentrations, and testosterone influences prostate growth, we also investigated whether the association of obesity, fasting glucose, and diabetes was influenced by testosterone. Serum testosterone and SHBG were measured in BLSA participants who had study visits between February 1993 and June 1998 and had adequate sera for analysis (31). For the present study, we linked the anthropometric, glucose, and hormone data sets. Of the 422 participants with 791 prostate volume measurements, glucose levels were available in 314 (548 measurements), and hormone levels were available in 225 (259 measurements).

Prostate imaging and volume determination

MRI was performed with a General Electric 1.5 Signa scanner with a phased array pelvic coil (General Electric Medical Systems, Milwaukee, WI) using the same protocol for each participant. Three scans were taken (T1, axial; T2, axial; and T2, sagittal), with the participant in the supine position. The T2 axial image was used to determine prostate volume because this view provides the most accurate volume assessment (32). Total prostate volumes were calculated using a semiautomated software image analysis system (32).

Outcome assessment

The primary outcome measure was MRI-determined total prostate volume. Total prostate volume was assessed as both a continuous outcome and a binary outcome: enlarged (≥40 cc) *vs.* nonenlarged (<40 cc). This 40-cc volume cutoff represents the threshold above which men who are not treated with medication or surgery will experience progressive deterioration of symptoms and significantly decreased urinary flow rates within 4 yr of follow-up (33). It also corresponded to the 75th percentile of all volume measures in this study population, which is another standard used for defining prostate enlargement and benign prostatic hyperplasia (34).

The secondary outcome measure was the severity of lower urinary tract symptoms as determined by the American Urological Association Symptom index, a validated questionnaire that scores the severity of urinary symptoms on a graded scale ranging from 0 (none) to 30 (severe) (35). Urinary symptom scores were available for 367 participants at 651 separate follow-up visits. The urinary symptom score was assessed as a continuous outcome using all observations and as a binary outcome using selected observations: no to mild symptoms (score < 7; n = 290 participants, 459 visits) and high-moderate to severe symptoms (≥15; n = 44 participants, 57 visits). Men with low-moderate symptoms (8–14; n = 102, 135 visits) were excluded to increase the specificity of the score in assessing benign prostatic hyperplasia for epidemiological studies (36).

Exposure assessment

Using weight and height measures at each participant visit, body mass index (BMI) was calculated (body weight in kilograms divided by the square of height in meters) and categorized based on national guidelines (37) as follows: less than 25 kg/m^2 (normal), 25–29.9 kg/m^2 (overweight), 30–34.9 kg/m^2 (obese), and more than or equal to 35 kg/m^2 (very obese).

Waist circumference was categorized as less than or equal to 102 cm (nonobese) and more than 102 cm (obese) (11). Waist-to-hip ratio was calculated from waist and hip circumference measures and was categorized as less than or equal to 0.90 (nonobese) and more than 0.90 (obese) (11).

Fasting plasma glucose concentration was determined as described previously (30). Fasting plasma glucose concentration was categorized in quartiles, and clinically elevated glucose was categorized as more than 110 ng/ml (elevated) and less than or equal to 110 ng/ml (normal) (11, 38). Diabetes mellitus was defined in accordance with American Diabetes Association criteria as described previously (30). Diagnoses were made by fasting glucose levels and/or history of treatment with insulin or oral hypoglycemic agents. Most participants with diabetes were non-insulin-dependent.

Serum testosterone and SHBG concentrations were determined as described previously (31). Free testosterone index, which correlates highly with serum free testosterone (39, 40) and is an indicator of the amount of serum testosterone able to diffuse into the prostate, was calculated as the molar ratio of testosterone to SHBG.

All samples for glucose and hormone concentrations were obtained between 0700 and 0930 h after an overnight fast.

Statistical analysis

All statistical analyses were performed using Stata version 8.0 (Stata Corporation, College Station, TX). Generalized estimating equations regression modeling (linear for prostate volume and lower urinary tract symptom score and logistic for prostate enlargement and high-moderate to severe lower urinary tract symptoms) was performed with robust variance estimates to account for multiple measures over time in the same individuals (41, 42). Data were assumed to be clustered by participant. All models included adjustment for age. Associations of BMI (national guideline cutoff points), fasting glucose (quartile and clinically elevated cutoff points), and diabetes with prostate enlargement and high moderate to severe lower urinary tract symptoms were determined by entering these exposures into the model as a series of indicator variables. Associations of obese waist circumference and obese waist-to-hip ratio with prostate enlargement and high moderate to severe lower urinary tract symptoms were also estimated. Tests for trends in the association of prostate enlargement and high moderate to severe lower urinary tract symptoms across levels of BMI, waist circumference, waist-to-hip ratio, and fasting glucose were performed by entering these measures into the

model as a continuous term, the coefficient for which was evaluated by the Wald test.

To assess whether overall obesity or central obesity was the greater contributor risk, we mutually adjusted BMI and waist circumference in a subanalysis. To assess whether fasting glucose, diabetes, or testosterone mediated or otherwise accounted for the effect of obesity, in subanalyses, we mutually adjusted the measures of obesity, fasting glucose, and diabetes and separately adjusted for serum testosterone concentration or the free testosterone index.

The sample sizes for this study were based on the availability of existing data. The smallest sample size for the primary exposures was for fasting glucose concentration. In the power calculations, we used the first measurement of MRI volume for each man (56 enlarged prostate, 259 nonenlarged prostate) and the observed prevalence of elevated fasting glucose in the men without an enlarged prostate (12.4%). We estimated the minimum odds ratio (OR) that would be detected as statistically significant with 80% power for a two-sided test with $\alpha = 0.05$ was 2.75. Thus, this study was powered to detect important associations but not modest associations.

Results

Participants

Of the 422 participants with prostate volume measurements, 291 (69%) were white, 95 (23%) were black, and 36 (8%) were of other ethnicities. The mean participant age for all visits was 58 yr (range, 27–84 yr), and the mean prostate volume was 33.0 cc (median, 29.3 cc; range, 8.7–237.3 cc). Participants with enlarged prostates were older (mean age, 64.8 yr; SD 9.8) than those with nonenlarged prostates (mean age, 54.7 yr; SD 12.2) ($P < 0.001$).

Compared with men with nonenlarged prostates, those with enlarged prostates had significantly higher age-adjusted weight and BMI (Table 1). The mean age-adjusted lower urinary tract symptom score among participants with a nonenlarged prostate (n = 513 observations) was 5.7 (SD 5.1) and among those with an enlarged prostate (n = 138 observations) was 8.0 (SD 5.8) ($P < 0.001$). Forty-five participants (n = 79 observations) were diagnosed with diabetes before or at the time of at least one visit during the study period.

Prostate volume

BMI was positively associated with prostate volume: for each 1 kg/m^2 increase in BMI, prostate volume increased by 0.41 cc (95% CI, −0.15 to 0.84; $P = 0.06$). Compared with men with normal range BMI, overweight and obese men had an increased odds of prostate enlargement ($P = 0.01$); the risk for very obese men was particularly high (Table 2). When restricting the analysis to men in the usual age range for diagnosis of benign prostatic hyperplasia (≥ 40 yr, n = 366), the associations of BMI with prostate volume ($P = 0.05$) and prostate enlargement ($P = 0.01$) were comparable with the overall cohort.

Waist circumference was not associated with prostate volume ($P = 0.28$). An obese waist circumference was nonstatistically significantly associated with prostate enlargement (Table 2). However, men at or above the 50th percentile of waist circumference (96.5 cm) had increased odds of prostate enlargement compared with men below the 50th percentile (OR, 1.58; 95% CI, 1.06–2.36). This association was attenuated after further adjustment for BMI (OR, 1.19; 95% CI, 0.72–1.97). There were no significant associations of waist-to-hip ratio with prostate volume ($P = 0.72$) or prostate enlargement (Table 2).

Fasting plasma glucose was not associated with prostate volume ($P = 0.31$). However, higher fasting plasma glucose concentration was positively associated with prostate enlargement (Table 3). The risk of prostate enlargement was confined to men in the highest quartile of fasting glucose level and was particularly pronounced among men with clinically elevated levels compared with men with normal levels (Table 3). Adjustment for BMI produced similar risk estimates for clinically elevated compared with normal fasting glucose levels (OR, 2.82; 95% CI, 1.56–5.08). Exclusion of men with diabetes at the time of prostate volume measurement (n = 49 observations) attenuated the associations between fasting glucose and prostate enlargement (Table 4).

Diabetes was positively associated with prostate volume ($P = 0.05$) and prostate enlargement (OR, 2.25; 95% CI, 1.23–4.11). Further adjustment for BMI resulted in slight attenuation of the association with prostate enlargement (OR, 1.90; 95% CI, 1.02–3.53).

Lower urinary tract symptoms

No significant associations were present for BMI ($P = 0.50$), waist circumference ($P = 0.96$), or waist-to-hip ratio ($P = 0.65$) with lower urinary tract symptom score. Although not statistically significant, the OR for high moderate to severe lower urinary tract symptoms was above 1 for obese BMI, waist circumference, and waist-to-hip ratio (Table 5). Both elevated fasting glucose (OR, 2.60; 95% CI, 1.01–6.70) and diabetes (OR, 2.80; 95% CI, 1.10–7.10) were associated with high-moderate to severe lower urinary tract symptoms, which persisted after adjustment for BMI ($P = 0.06$ and 0.07, respectively).

Adjustment for testosterone or free testosterone index

Adjustment for testosterone or free testosterone index did not attenuate the associations of BMI ($P = 0.04$ and 0.001,

TABLE 1. Age-adjusted anthropometric characteristics of men with nonenlarged (<40 cc) *vs.* enlarged (≥40 cc) MRI-determined prostate volume among 422 men in the BLSA, 1993–2002

	Prostate volume < 40 cc (n = 610 observations) [mean (SD)]	Prostate volume ≥ 40 cc (n = 181 observations) [mean (SD)]	*P*
Height (cm)	176.6 (9.9)	176.7 (9.4)	0.97
Weight (kg)	85.5 (17.3)	88.8 (24.2)	0.04
BMI (kg/m^2)	27.4 (4.9)	28.4 (6.7)	0.03
Waist circumference (cm)	96.1 (14.8)	97.6 (16.1)	0.17
Waist-to-hip ratio	0.94 (0.07)	0.94 (0.08)	0.62

TABLE 2. Age-adjusted ORs for prostate enlargement (MRI-determined volume ≥40 cc *vs.* <40 cc) by measures of obesity in 422 men (791 observations) in the BLSA, 1993–2002

	BMI (kg/m^2)				*P*
	<25 (normal)	25.0–29.9 (overweight)	30–34.9 (obese)	≥35 (severely obese)	
No. of observations	202	401	154	34	
OR	1.00	1.41	1.27	3.52	0.01
95% CI		0.84–2.37	0.68–2.39	1.45–8.56	
	Waist circumference (cm)				
	≤102	>102			
No. of observations	548	243			
OR	1.00	1.17			0.10
95% CI		0.77–1.79			
	Waist-to-hip ratio				
	≤0.90	>0.90			
No. of observations	216	575			
OR	1.00	0.78			0.70
95% CI		0.50–1.24			

respectively) or elevated fasting glucose ($P = 0.003$ and $P < 0.001$, respectively) with prostate enlargement. For the association of diabetes with prostate enlargement, further adjustment for serum total testosterone ($P < 0.002$) or free testosterone index ($P < 0.001$) strengthened the results.

Discussion

In this cohort of community-dwelling U.S. men, obesity, elevated fasting glucose, and diabetes were associated with prostate enlargement, an objective indicator of benign prostatic hyperplasia. Compared with their peers with normal range values, very obese men were 3.5-fold more likely, men with elevated glucose 3-fold more likely, and diabetic men 2-fold more likely to have an enlarged prostate. Overall obesity, rather than central obesity, appeared to be the more important predictor. The association for elevated fasting glucose in men without diabetes was attenuated, suggesting that larger perturbations in glucose homeostasis were more strongly associated with prostate enlargement. These results indicate that obesity, elevated fasting glucose, and diabetes are risk factors for benign prostatic hyperplasia and are consistent with previous observations of obesity, serum insulin, and prostate volume (20, 22–26).

Overall obesity, fasting glucose, and diabetes were also positively associated with lower urinary tract symptoms. Unlike the findings for prostate enlargement, these results did not attain statistical significance, in part because of the smaller sample size available for assessment of lower urinary tract symptoms. Lower urinary tract symptoms are often a clinical manifestation of benign prostatic hyperplasia, and the findings of the present study were similar to those observed in two prior observational studies. Obese men aged 40–75 yr enrolled in the U.S. Health Professionals Follow-up Study had increased frequency and severity of obstructive urinary symptoms (12), as did those aged 60 yr or older in the Third National Health and Nutrition Examination Survey (13). However, neither of these two studies analyzed the association of obesity with prostate volume. Lower urinary tract symptoms alone represent a nonspecific surrogate for benign prostatic hyperplasia, and symptom severity does not correlate with prostate volume (43). Volume-determined prostate enlargement, however, is a specific measure of benign prostatic hyperplasia that strongly predicts adverse clinical outcomes, including acute urinary retention, renal failure, and need for noncancer prostate surgery (18, 19, 44, 45).

Previous etiological models of benign prostatic hyperplasia have focused primarily on the role of sex steroid hormones (5, 6). Both androgens and estrogens may stimulate prostate growth. Adipose tissue, which accumulates with age, aromatizes circulating testosterone into estrogen (46), and it has been hypothesized that alterations in the balance

TABLE 3. Age-adjusted ORs for prostate enlargement (MRI-determined volume ≥40 cc *vs.* <40 cc) by fasting plasma glucose concentration in 314 men (548 observations) in the BLSA, 1993–2001

	By quartile				*P*
	1	2	3	4	
Fasting plasma glucose (ng/dl)	<90	90–95.9	96–104	>104	
No. of observations	113	134	157	144	
OR	1.00	1.09	0.63	2.00	0.03[a]
95% CI		0.53–2.26	0.33–1.46	1.06–3.78	
	By cutoff for clinical elevation (11, 38)				
Fasting plasma glucose (ng/dl)	≤110		>110		
No. of observations	465		83		
OR	1.00		2.98		<0.001[b]
95% CI			1.70–5.23		

[a] Comparing 4th with 1st quartiles.
[b] Comparing elevated (>110 ng/dl) with nonelevated (≤110 ng/dl).

TABLE 4. Age-adjusted ORs for prostate enlargement (MRI-determined volume ≥ 40 cc *vs.* < 40 cc) by fasting plasma glucose concentration in 290 men (499 observations) without diabetes mellitus in the BLSA, 1993–2001

	By quartile				*P*
	1	2	3	4	
Fasting plasma glucose (ng/dl)	<90	90–95.9	96–102	>102	
No. of observations	111	131	135	122	
OR	1.00	1.18	0.67	1.34	0.42[a]
95% CI		0.57–2.46	0.31–1.47	0.65–2.77	
	By cutoff for clinical elevation (11, 38)				
Fasting plasma glucose (ng/dl)	≤110		>110		
No. of observations	457		42		
OR	1.00		1.70		0.16[b]
95% CI			0.81–3.56		

[a] Comparing 4th with 1st quartiles.
[b] Comparing elevated (>110 ng/dl) with nonelevated (≤110 ng/dl).

between testosterone and estrogen levels in prostate tissue with age may contribute to benign prostatic hyperplasia (47). In our study, the associations of obesity, elevated fasting glucose, and diabetes with prostate enlargement remained significant after adjusting for serum total or calculated free testosterone. These findings suggest that obesity and abnormal glucose homeostasis potentially influence prostate growth through mechanisms other than testosterone.

An alternative mechanism for benign prostatic hyperplasia may be related to metabolic disturbances. Obesity and elevated fasting glucose are components of the metabolic syndrome (11); both obesity and the metabolic syndrome are associated with systemic inflammation and oxidative stress (48). Inflammation has been implicated as a primary stimulus for prostate carcinogenesis (49), and it is possible that benign prostatic hyperplasia represents an alternate, nonmalignant pathway of unregulated prostate growth promoted by oxidative stress, inflammatory mediators, and IGFs (36, 50, 51). Indeed, analyses of surgical specimens have shown that benign prostatic hyperplasia is usually associated with inflammation (52–54) and that the extent and severity of the inflammation corresponds to the amount of prostate enlargement (55).

The finding in our study that obesity and abnormal glucose homeostasis are associated with benign prostatic hyperplasia is consistent with global geographic differences in the distribution and severity of benign prostatic hyperplasia. Southeast Asian men have a lower prevalence and severity of autopsy-diagnosed benign prostatic hyperplasia than age-matched North American men (56). Likewise, although Chinese men have smaller prostates than age-matched Australian men, this difference disappears in native-born Chinese men who immigrate to Australia, implying that prostate growth may accelerate after exposure to a Western lifestyle (57). Because obesity, impaired glucose homeostasis, and diabetes result primarily from physical inactivity and dietary factors endemic to Westernized societies (58), our results, together with the geographic distribution of benign prostatic hyperplasia, indicate that lifestyle and diet may possibly contribute to benign prostatic hyperplasia pathogenesis. Associations of benign prostatic hyperplasia with decreased physical activity (17, 59), increased beef intake (60), and decreased vegetable intake (61) further support this connection.

A substantial strength of the present study is its unique use of repeated, MRI-determined prostate volume measures. MRI is highly accurate for determining true prostate volume (62) and, unlike prior studies of prostate volume, half of the participants contributed at least two different sets of measures over an 8-yr period (although the potential existed for nondifferential measurement error of prostate volume). Another strength of this study is the relevance of the study

TABLE 5. Age-adjusted ORs for high-moderate to severe lower urinary tract symptoms (American Urological Association symptom index ≥ 15 *vs.* ≤ 7) by measures of obesity in 329 men (516 observations) in the BLSA, 1993–2001

	BMI (kg/m^2)				*P*
	<25 (normal)	25.0–29.9 (overweight)	30–34.9 (obese)	≥35 (severely obese)	
No. of observations	146	252	95	23	
OR	1.00	2.18	2.15	3.47	0.17
95% CI		0.68–7.02	0.55–8.39	0.54–22.3	
	Waist circumference (cm)				
	≤102	>102			
No. of observations	360	156			
OR	1.00	1.54			0.30
95% CI		0.77–3.09			
	Waist-to-hip ratio				
	≤0.90	>0.90			
No. of observations	161	355			
OR	1.00	1.99			0.30
95% CI		0.90–4.44			

population composition: older, community-dwelling men. Although the BLSA cohort has limited racial variation, and most participants represent higher socioeconomic and educational levels, the prevalence of benign prostatic hyperplasia does not appear to vary greatly by race in the United States (63, 64). In the analysis, we took into account two major predictors of prostate volume: age and serum testosterone level. However, we cannot rule out confounding by possible modifiable risk factors for benign prostatic hyperplasia, including physical activity (17, 59), smoking (17), and alcohol intake (65). We also cannot rule out that our findings for obesity, fasting glucose, and diabetes with prostate enlargement are due to their correlations with other components of the metabolic syndrome, such as dyslipidemia.

In summary, obesity, elevated fasting plasma glucose, and diabetes are risk factors for benign prostatic hyperplasia. These results suggest that the rising prevalences of obesity and diabetes (27, 28), coupled with the rapid aging of the U.S. population (66), may contribute to an increase in benign prostatic hyperplasia prevalence and exacerbate the problems this disease poses to public health. Still, the potential link between benign prostatic hyperplasia and physical inactivity and diet also raises the possibility that the same general practices recommended for promotion of good health, including exercise and healthy diet, may alter the natural history of benign prostatic hyperplasia or prevent or attenuate its clinical manifestations.

Acknowledgments

Received December 22, 2005. Accepted March 31, 2006.

Address all correspondence and requests for reprints to: J. Kellogg Parsons, M.D., M.H.S., Division of Urology, University of California San Diego, 200 West Arbor Drive, San Diego, California 21287. E-mail: k0parsons@ucsd.edu.

This work was supported by the Intramural Research Program, National Institute of Aging (support for the design and conduct of the study; collection, management, and interpretation of the data; and approval of the manuscript) and by GlaxoSmithKline (discretionary funding to support research in benign prostatic hyperplasia; grant to H.B.C.). GlaxoSmithKline did not participate in any way in the design of this study; the collection, statistical analysis, or interpretation of the data; the interpretation of the results; or in the writing of this paper.

References

1. **Roehrborn CG, McConnell JD** 2002 Etiology, pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Wein AW, Vaugh E, eds. Campbell's urology. Philadelphia: Lipincott Williams and Wilkins; 1297–1336
2. **Ziada A, Rosenblum M, Crawford ED** 1999 Benign prostatic hyperplasia: an overview. Urology 53:1–6
3. **Marberger M, Harkaway R, de la Rosette J** 2004 Optimising the medical management of benign prostatic hyperplasia. Eur Urol 45:411–419
4. **Wei JT, Calhoun E, Jacobsen SJ** 2005 Urologic diseases in America project: benign prostatic hyperplasia. J Urol 173:1256–1261
5. **Coffey DS, Walsh PC** 1990 Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 17:461–475
6. **Wilson JD** 1980 The pathogenesis of benign prostatic hyperplasia. Am J Med 68:745–756
7. **Cohen P, Peehl DM, Lamson G, Rosenfeld RG** 1991 Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 73:401–407
8. **Monti S, Di Silverio F, Lanzara S, Varasano P, Martini C, Tosti-Croce C, Sciarra F** 1998 Insulin-like growth factor-I and -II in human benign prostatic hyperplasia: relationship with binding proteins 2 and 3 and androgens. Steroids 63:362–366
9. **Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW** 2002 Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 168:599–604
10. **Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Sesterhenn IA, Mostofi FK, Fraumeni Jr JF, Hsing AW** 2002 Insulin-like growth factors and risk of benign prostatic hyperplasia. Prostate 52:98–105
11. **Haffner S, Taegtmeyer H** 2003 Epidemic obesity and the metabolic syndrome. Circulation 108:1541–1545
12. **Giovannucci E, Rimm EB, Chute CG, Kawachi I, Colditz GA, Stampfer MJ, Willett WC** 1994 Obesity and benign prostatic hyperplasia. Am J Epidemiol 140:989–1002
13. **Rohrmann S, Smit E, Giovannucci E, Platz EA** 2004 Associations of obesity with lower urinary tract symptoms and noncancer prostate surgery in the Third National Health and Nutrition Examination Survey. Am J Epidemiol 159:390–397
14. **Bourke JB, Griffin JP** 1966 Hypertension, diabetes mellitus, and blood groups in benign prostatic hypertrophy. Br J Urol 38:18–23
15. **Seitter WR, Barrett-Connor E** 1992 Cigarette smoking, obesity, and benign prostatic hypertrophy: a prospective population-based study. Am J Epidemiol 135:500–503
16. **Glynn RJ, Campion EW, Bouchard GR, Silbert JE** 1985 The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol 121:78–90
17. **Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB** 2001 Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 54:935–944
18. **McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group** 2003 The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387–2398
19. **Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, Castellanos R, Coffield S, Saltzman B, Resnick M, Cook TJ, Waldstreicher J** 1999 Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 53:473–480
20. **Matsuda T, Abe H, Suda K** 2004 [Relation between benign prostatic hyperplasia and obesity and estrogen]. Rinsho Byori 52:291–294 (Japanese)
21. **Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D** 1998 Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1:157–162
22. **Joseph MA, Wei JT, Harlow SD, Cooney KA, Dunn RL, Jaffe CA, Montie JE, Schottenfeld D** 2002 Relationship of serum sex-steroid hormones and prostate volume in African American men. Prostate 53:322–329
23. **Soygur T, Kupeli B, Aydos K, Kupeli S, Arikan N, Muftuoglu YZ** 1996 Effect of obesity on prostatic hyperplasia: its relation to sex steroid levels. Int Urol Nephrol 28:55–59
24. **Daniell HW** 1993 Larger prostatic adenomas in obese men with no associated increase in obstructive uropathy. J Urol 149:315–317
25. **Ochiai A, Fritsche HA, Babaian RJ** 2005 Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer. Urology 66:819–823
26. **Hammarsten J, Hogstedt B** 2001 Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 39:151–158
27. **Flegal KM, Carroll MD, Ogden CL, Johnson CL** 2002 Prevalence and trends in obesity among US adults, 1999–2000. JAMA 288:1723–1727
28. **Ford ES, Giles WH, Dietz WH** 2002 Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287:356–359
29. **Shock NW, Greulich RC, Andres R, Arenberg D, Costa Jr PT, Lakatta EG, Tobin JD** 1984 Normal Human Aging: The Baltimore Longitudinal Study of Aging. Washington, DC: National Institutes of Health; 84–2450
30. **Blake DR, Meigs JB, Muller DC, Najjar SS, Andres R, Nathan DM** 2004 Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging. Diabetes 53:2095–2100
31. **Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR** 2001 Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86:724–731
32. **Williams AM, Simon I, Landis PK, Moser C, Christens-Barry W, Carter HB, Metter EJ, Partin AW** 1999 Prostatic growth rate determined from MRI data: age-related longitudinal changes. J Androl 20:474–480
33. **Roehrborn CG, Boyle P, Bergner D, Gray T, Gittelman M, Shown T, Melman A, Bracken RB, deVere White R, Taylor A, Wang D, Waldstreicher J** 1999 Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology 54:662–669
34. **Wright EJ, Fang J, Metter EJ, Partin AW, Landis P, Chan DW, Carter HB** 2002 Prostate specific antigen predicts the long-term risk of prostate enlargement:

results from the Baltimore Longitudinal Study of Aging. J Urol 167:2484–2487; discussion 2487–2488
35. **Barry MJ, Fowler Jr FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT** 1992 The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148:1549–1557; discussion 1564
36. **Suzuki S, Platz EA, Kawachi I, Willett WC, Giovannucci E** 2002 Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia. Am J Clin Nutr 75:689–697
37. **National Heart, Lung, and Blood Institute** 1998 Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Rockville, MD: National Heart, Lung, and Blood Institute
38. 1997 Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183–1197
39. **Vermeulen A, Verdonck L, Kaufman JM** 1999 A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666–3672
40. **Miller KK, Rosner W, Lee H, Hier J, Sesmilo G, Schoenfeld D, Neubauer G, Klibanski A** 2004 Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J Clin Endocrinol Metab 89:525–533
41. **Rogers WH** 1993 Regression standard errors in clustered samples. Stata Tech Bull 13:19–23
42. **Williams RL** 2000 A note on robust variance estimation for cluster-correlated data. Biometrics 56:645–646
43. 2003 AUA guideline on management of benign prostatic hyperplasia 2003: I. Diagnosis and treatment recommendations. J Urol 170:530–547
44. **Mochtar CA, Kiemeney LA, Laguna MP, van Riemsdijk MM, Barnett GS, Debruyne FM, de la Rosette JJ** 2005 Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with α1-blockers and watchful waiting. Urology 65:300–305
45. **Marberger MJ, Andersen JT, Nickel JC, Malice MP, Gabriel M, Pappas F, Meehan A, Stoner E, Waldstreicher J** 2000 Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials. Eur Urol 38:563–568
46. **Hautanen A** 2000 Synthesis and regulation of sex hormone-binding globulin in obesity. Int J Obes Relat Metab Disord 24(Suppl 2):S64–S70
47. **Shibata Y, Ito K, Suzuki K, Nakano K, Fukabori Y, Suzuki R, Kawabe Y, Honma S, Yamanaka H** 2000 Changes in the endocrine environment of the human prostate transition zone with aging: simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition. Prostate 42:45–55
48. **Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I** 2004 Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114:1752–1761
49. **Nelson WG, De Marzo AM, Isaacs WB** 2003 Prostate cancer. N Engl J Med 349:366–381
50. **Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE** 2000 The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21:215–244
51. **Wang W, Bergh A, Damber JE** 2004 Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 61:60–72
52. **Nickel JC, Downey J, Young I, Boag S** 1999 Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 84:976–981
53. **Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M, Zechner O, Steiner GE** 1992 Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 66:96–107
54. **Anim JT, Udo C, John B** 1998 Characterisation of inflammatory cells in benign prostatic hyperplasia. Acta Histochem 100:439–449
55. **Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA, Sciarra A** 2003 Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 43:164–175
56. **Magi-Galluzi C, Parsons JK, Fedor H, Platz EA, Miller GJ, De Marzo AM** 2004 The prevalence and extent of autopsy benign prostatic hyperplasia (BPH) is less in Southeast Asian men than North American men. J Urol 171(Suppl):406
57. **Jin B, Turner L, Zhou Z, Zhou EL, Handelsman DJ** 1999 Ethnicity and migration as determinants of human prostate size. J Clin Endocrinol Metab 84:3613–3619
58. **Roberts CK, Barnard RJ** 2005 Effects of exercise and diet on chronic disease. J Appl Physiol 98:3–30
59. **Platz EA, Kawachi I, Rimm EB, Colditz GA, Stampfer MJ, Willett WC, Giovannucci E** 1998 Physical activity and benign prostatic hyperplasia. Arch Intern Med 158:2349–2356
60. **Chyou PH, Nomura AM, Stemmermann GN, Hankin JH** 1993 A prospective study of alcohol, diet, and other lifestyle factors in relation to obstructive uropathy. Prostate 22:253–264
61. **Araki H, Watanabe H, Mishina T, Nakao M** 1983 High-risk group for benign prostatic hypertrophy. Prostate 4:253–264
62. **Rahmouni A, Yang A, Tempany CM, Frenkel T, Epstein J, Walsh P, Leichner PK, Ricci C, Zerhouni E** 1992 Accuracy of in-vivo assessment of prostatic volume by MRI and transrectal ultrasonography. J Comput Assist Tomogr 16:935–940
63. **Platz EA, Kawachi I, Rimm EB, Willett WC, Giovannucci E** 2000 Race, ethnicity and benign prostatic hyperplasia in the health professionals follow-up study. J Urol 163:490–495
64. **Platz EA, Smit E, Curhan GC, Nyberg LM, Giovannucci E** 2002 Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U.S. men. Urology 59:877–883
65. **Crispo A, Talamini R, Gallus S, Negri E, Gallo A, Bosetti C, La Vecchia C, Dal Maso L, Montella M** 2004 Alcohol and the risk of prostate cancer and benign prostatic hyperplasia. Urology 64:717–722
66. **Daviglus ML, Liu K, Yan LL, Pirzada A, Manheim L, Manning W, Garside DB, Wang R, Dyer AR, Greenland P, Stamler J** 2004 Relation of body mass index in young adulthood and middle age to Medicare expenditures in older age. JAMA 292:2743–2749

JCEM is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.